The role of surgical reexploration following chemotherapy in XXXX .

@entity1 @entity43 @entity66 @entity900 @entity5805 @entity1321 @entity1168
Two hundred and eighty three @entity1 with FIGO Stages III-IV @entity43 were entered on a randomized trial of @entity5805 with or without @entity900 . Eighty two of these @entity1 have subsequently undergone surgical reexploration. Ten of these were for surgical indications ( @entity1321 , etc.), and 7 were interval reexplorations at about 6 months on @entity1 who had not been adequately debulked at primary surgery. The remaining 65 @entity1 had elective operations after 12 months chemotherapy, and in 52 of these there was no pre-operative clinical evidence of @entity66 . @entity1168 ( @entity1168 ) was similar in the 2 treatment arms (8% v 9.7%); 42.3% of @entity1 in apparent remission at 12 months had negative reexploration and 57.5% of these were alive after 4 years (post-reexploration median survival greater than 4 1/2 years). The remaining 57.7% of @entity1 had @entity66 at reexploration and their 4-year survival was 15% (median survival 73 weeks). A further group of 13 @entity1 had 'responding' and probably resectable @entity66 at 12 months. These @entity1 were reexplored with a view to secondary debulking. Their 4-year postoperation survival was 15% (median survival, 70 weeks). There were 9 @entity1 who, though in apparent remission at 12 months, were not subjected to surgical reexploration. The median survival for this group was 33 weeks, calculated from the mean theoretical time when they should have had reexploration. This was significantly inferior to the results for the 52 @entity1 , also in apparent remission, who underwent reexploration (4-year survival 32.5%, median survival 123 weeks, p = 0.002).
